A Phase 1 interventional study of Ramucirumab (IMC-1121B) and Irinotecan in Colorectal Carcinoma, sponsored by Eli Lilly and Company. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-10-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Colorectal Neoplasms by Eli Lilly and Company — 4 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Eli Lilly and Company.
Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, this one is the 32nd largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2011, is one of 14 in phase 1, and was the 21st registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →4 of the 37 studies in Colorectal Neoplasms by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, China, Germany and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, China, Spain
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 19 · Phase 3 3
First in 2002; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 103 across the 34 interventional studies. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Colorectal Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to investigate the safety and tolerability of the anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody Ramucirumab (IMC-1121B) in combination with irinotecan, levofolinate, and 5-fluorouracil (FOLFIRI) in Japanese participants with advanced colorectal carcinoma (CRC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Ramucirumab (IMC-1121B) · Drug: Irinotecan · Drug: levofolinate · Drug: 5-Fluorouracil (5-FU)
Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
Also known as: IMC-1121B, Ramucirumab, LY3009806
IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
IV infusion, 200 mg/m² every 2 weeks
400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period
DLTs were adverse events (AEs) possibly related to study drug that met the National Cancer Institute's Common Terminology Criteria for AEs (NCI CTCAE, version 4.03): Grade 4 neutropenia ≥7 days or ≥Grade 3 with bacteremia or sepsis; Absolute neutrophil count \<1.0x10\^9/Liters with fever ≥38.3°Celsius requiring intravenous antibiotic therapy; Grade 4 thrombocytopenia or ≥Grade 3 with bleeding requiring platelet transfusion; ≥Grade 3 altered coagulation tests and no anticoagulation; ≥Grade 4 or uncontrolled hypertension; ≥Grade 3 non-hematologic toxicity (except non-clinically significant Grade 3 events like electrolyte abnormality, hypersensitivity, and arthralgia/myalgia); urine protein \>3 grams/24 hours; study drug-related toxicity causing Cycle 3, Day 1 treatment delay until Day 44 or later. Grade 3 or Grade 4 infusion-related reaction (hypersensitivity) due to ramucirumab or FOLFIRI, not a DLT.
Time frame: Day 1, Cycle 1 through Day 1, Cycle 3 (1 cycle=14 days)
Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events
Data are presented for the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade ≥3 TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab. Events related to Irinotecan, Levofolinate, and 5-fluorouracil (5-FU) were reported separately. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline to end of study (up to 49.3 weeks) plus 37 day follow-up
Number of Participants With Serum Anti-IMC-1121B Antibodies (Immunogenicity)
Time frame: Day 1 of Cycle 5 (Week 9), Cycle 6 (Week 11), Cycle 7 (Week 13), and Cycle 9 (Week 17) [(1 cycle=14 days)]
Maximum Concentration (Cmax) of Ramucirumab
The Cmax of ramucirumab in serum on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered Cmax at steady state (Cmax,ss), is reported.
Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Area Under the Curve (AUC) of Ramucirumab
Reported for Day 1, Cycle 1 is AUC from time 0 extrapolated to infinity \[AUC(0-inf)\] and for Day 1, Cycle 5 is AUC over the dosing interval at steady state AUC(tau,ss).
Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Half Life (t1/2) of Ramucirumab
t1/2 is the time required for the plasma/serum concentration to decrease 50%.
Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Clearance (CL) of Ramucirumab
The total body CL of ramucirumab on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered CL at steady state (CLss), is reported.
Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Steady State Volume of Distribution (Vss) of Ramucirumab
Vss is the theoretical volume in which the total amount of study drug would need to be uniformly distributed during steady state to produce the same concentration as it is in plasma/serum.
Time frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]
Best overall response evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 millimeters (mm). Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Progressive Disease (PD): an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum on study (included baseline sum if that was the smallest on study). In addition, the sum must have demonstrated an absolute increase of at least 5 mm (the appearance of 1 or more new lesions was considered progression). Stable Disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.
Time frame: Every 8 weeks until PD (up to 49 weeks)
| Milestone | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Started | 6 |
| Completed dlt assessment period | 5 |
| Completed | 6 |
| Not completed | 0 |
DLTs were adverse events (AEs) possibly related to study drug that met the National Cancer Institute's Common Terminology Criteria for AEs (NCI CTCAE, version 4.03): Grade 4 neutropenia ≥7 days or ≥Grade 3 with bacteremia or sepsis; Absolute neutrophil count \<1.0x10\^9/Liters with fever ≥38.3°Celsius requiring intravenous antibiotic therapy; Grade 4 thrombocytopenia or ≥Grade 3 with bleeding requiring platelet transfusion; ≥Grade 3 altered coagulation tests and no anticoagulation; ≥Grade 4 or uncontrolled hypertension; ≥Grade 3 non-hematologic toxicity (except non-clinically significant Grade 3 events like electrolyte abnormality, hypersensitivity, and arthralgia/myalgia); urine protein \>3 grams/24 hours; study drug-related toxicity causing Cycle 3, Day 1 treatment delay until Day 44 or later. Grade 3 or Grade 4 infusion-related reaction (hypersensitivity) due to ramucirumab or FOLFIRI, not a DLT.
| participants | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period | 1 |
Data are presented for the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade ≥3 TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab. Events related to Irinotecan, Levofolinate, and 5-fluorouracil (5-FU) were reported separately. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.
| participants | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Related TEAE | 6 |
| Related SAE | 0 |
| Related Grade ≥3 TEAE | 3 |
| Related AE leading to discontinuation | 2 |
| participants | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Day 1, Cycle 5 (n=5) | 0 |
| Day 1, Cycle 6 (n=1) | 0 |
| Day 1, Cycle 7 (n=3) | 0 |
| Day 1, Cycle 9 (n=4) | 0 |
The Cmax of ramucirumab in serum on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered Cmax at steady state (Cmax,ss), is reported.
| micrograms per milliliter (mcg/mL) | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Day 1, Cycle 1 (n=6) | 245 ± 6 |
| Day 1, Cycle 5 (n=2) | 267 ± 11 |
Reported for Day 1, Cycle 1 is AUC from time 0 extrapolated to infinity \[AUC(0-inf)\] and for Day 1, Cycle 5 is AUC over the dosing interval at steady state AUC(tau,ss).
| micrograms*day/milliliter (mcg*day/mL) | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Day 1, Cycle 1 (n=4) | 1600 ± 15 |
| Day 1, Cycle 5 (n=2) | 1690 ± 38 |
t1/2 is the time required for the plasma/serum concentration to decrease 50%.
| days | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Day 1, Cycle 1 (n=6) | 7.38 ± 19 |
| Day 1, Cycle 5 (n=2) | 8.55 ± 2 |
The total body CL of ramucirumab on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered CL at steady state (CLss), is reported.
| milliliters per hour (mL/hr) | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Day 1, Cycle 1 (n=4) | 11.4 ± 26 |
| Day 1, Cycle 5 (n=2) | 10.4 ± 61 |
Vss is the theoretical volume in which the total amount of study drug would need to be uniformly distributed during steady state to produce the same concentration as it is in plasma/serum.
| Liters (L) | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Day 1, Cycle 1 (n=4) | 2.51 ± 25 |
| Day 1, Cycle 5 (n=2) | 3.06 ± 56 |
Best overall response evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 millimeters (mm). Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Progressive Disease (PD): an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum on study (included baseline sum if that was the smallest on study). In addition, the sum must have demonstrated an absolute increase of at least 5 mm (the appearance of 1 or more new lesions was considered progression). Stable Disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.
| participants | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Complete Response (CR) | 0 |
| Partial Response (PR) | 1 |
| Stable Disease (SD) | 4 |
| Progressive Disease (PD) | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FOLFIRI Plus Ramucirumab (IMC-1121B) | — | 0/6 (0%) | 6/6 (100%) |
| Event | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 5/6 |
| DIARRHOEAGastrointestinal disorders | 5/6 |
| STOMATITISGastrointestinal disorders | 5/6 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 4/6 |
| VOMITINGGastrointestinal disorders | 4/6 |
| DECREASED APPETITEMetabolism and nutrition disorders | 4/6 |
| NAUSEAGastrointestinal disorders | 3/6 |
| FATIGUEGeneral disorders | 3/6 |
| UTERINE HAEMORRHAGEReproductive system and breast disorders | 1/2 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 3/6 |
Safety population: Participants who received any quantity of study medication.
| Age, Categorical(Participants) | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 2 |
| Sex: Female, Male(Participants) | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Female | 2 |
| Male | 4 |
| Race/Ethnicity, Customized(participants) | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Asian | 6 |
| Region of Enrollment(participants) | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| Japan | 6 |
| Eastern Cooperative Oncology Group (ECOG) performance status(participants) | FOLFIRI Plus Ramucirumab (IMC-1121B) |
|---|---|
| 0 - Fully active | 3 |
| 1 - Ambulatory, restricted strenuous activity | 3 |
The record gives a start of Feb 2011, a primary completion of Feb 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab